Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_47_библиотеки_им_акад_М_И_Перельмана
.pdf
72
139. Guanabens N, Pares A, Ros I, Caballeria L, Pons F, Vidal S, Monegal A, etal. Severity of
cholestasis and advanced histological stage but not menopausal status are the major risk fac-
tors for osteoporosis in primary biliary cirrhosis. J Hepatol. 2005;42:573–7.
140. Guanabens N, Cerda D, Monegal A, Pons F, Caballeria L, Peris P, Pares A.Low bone mass
and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis.
Gastroenterology. 2010;138:2348–56.
141. McCaughan GW, Feller RB.Osteoporosis in chronic liver disease: pathogenesis, risk factors,
and management. Dig Dis. 1994;12:223–31.
142. Herlong HF, Recker RR, Maddrey WC.Bone disease in primary biliary cirrhosis: histologic
features and response to 25-hydroxyvitamin D.Gastroenterology. 1982;83:103–8.
143. Hodgson SF, Dickson ER, Eastell R, Eriksen EF, Bryant SC, Riggs BL.Rates of cancellous
bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis. Bone.
1993;14:819–27.
144. Pares A, Guanabens N, Rodes J. Gene polymorphisms as predictors of decreased bone
mineral density and osteoporosis in primary biliary cirrhosis. Eur J Gastroenterol Hepatol.
2005;17:311–5.
145. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD.Bone disease in primary biliary
cirrhosis: independent indicators and rate of progression. J Hepatol. 2001;35:316–23.
146. Frith J, Kerr S, Robinson L, Elliott C, Ghazala C, Wilton K, Pairman J, etal. Primary biliary
cirrhosis is associated with falls and signicant fall related injury. QJM. 2010;103:153–61.
147. Green JH, Bramley PN, Losowsky MS.Are patients with primary biliary cirrhosis hyper-
metabolic? A comparison between patients before and after liver transplantation and controls.
Hepatology. 1991;14:464–72.
148. Koulaouzidis A, Bhat S, Moschos J. Skin manifestations of liver diseases. Ann Hepatol.
2007;6:181–4.
149. Reynolds TB.The “buttery” sign in patients with chronic jaundice and pruritus. Ann Intern
Med. 1973;78:545–6.
150. Heathcote J.Autoimmune cholangitis. Gut. 1997;40:440–2.
151. Heathcote J. Primary biliary cirrhosis with features of autoimmune hepatitis. Curr
Gastroenterol Rep. 2001;3:60–4.
152. Michieletti P, Wanless IR, Katz A, Scheuer PJ, Yeaman SJ, Bassendine MF, Palmer JM, etal.
Antimitochondrial antibody negative primary biliary cirrhosis: a distinct syndrome of auto-
immune cholangitis. Gut. 1994;35:260–5.
153. Lacerda MA, Ludwig J, Dickson ER, Jorgensen RA, Lindor KD.Antimitochondrial antibody-
negative primary biliary cirrhosis. Am J Gastroenterol. 1995;90:247–9.
154. Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, etal.
Comparison of the clinical features and clinical course of antimitochondrial antibody- positive
and -negative primary biliary cirrhosis. Hepatology. 1997;25:1090–5.
155. Migliaccio C, Van de Water J, Ansari AA, Kaplan MM, Coppel RL, Lam KS, Thompson RK,
etal. Heterogeneous response of antimitochondrial autoantibodies and bile duct apical stain-
ing monoclonal antibodies to pyruvate dehydrogenase complex E2: the molecule versus the
mimic. Hepatology. 2001;33:792–801.
156. Shimoda S, Nakamura M, Ishibashi H, Hayashida K, Niho Y.HLA DRB4 0101-restricted
immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary bili-
ary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. J Exp Med.
1995;181:1835–45.
157. Wing K, Sakaguchi S.Regulatory T cells exert checks and balances on self tolerance and
autoimmunity. Nat Immunol. 2010;11:7–13.
158. Marshak-Rothstein A.Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol.
2006;6:823–35.
159. Shimoda S, Van de Water J, Ansari A, Nakamura M, Ishibashi H, Coppel R, Lake J, et al.
Identication and precursor frequency analysis of a common T cell epitope motif in mito-
chondrial autoantigens in primary biliary cirrhosis. J Clin Invest. 1998;102:1831–40.
N. V. Bergasa
https://t.me/medicina_free
73
160. Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote
EJ.Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to
therapy with ursodeoxycholic acid. Hepatology. 2002;35:409–13.
161. Su CW, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Lee PC, et al. Natural history and
prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years.
Liver Int. 2008;28:1305–13.
162. Shimoda S, Miyakawa H, Nakamura M, Ishibashi H, Kikuchi K, Kita H, Niiro H, etal. CD4
T-cell autoreactivity to the mitochondrial autoantigen PDC-E2 in AMA-negative primary
biliary cirrhosis. J Autoimmun. 2008;31:110–5.
163. Joplin R, Lindsay JG, Johnson GD, Strain A, Neuberger J.Membrane dihydrolipoamide
acetyltransferase (E2) on human biliary epithelial cells in primary biliary cirrhosis. Lancet.
1992;339:93–4.
164. Van de Water J, Turchany J, Leung PS, Lake J, Munoz S, Surh CD, Coppel R, etal. Molecular
mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule
cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest. 1993;91:2653–64.
165. Brown WR, Kloppel TM.The liver and IgA: immunological, cell biological and clinical
implications. Hepatology. 1989;9:763–84.
166. Malmborg AC, Shultz DB, Luton F, Mostov KE, Richly E, Leung PS, Benson GD, etal.
Penetration and co-localization in MDCK cell mitochondria of IgA derived from patients
with primary biliary cirrhosis. J Autoimmun. 1998;11:573–80.
167. Russell MW, Sibley DA, Nikolova EB, Tomana M, Mestecky J. IgA antibody as a non-
inammatory regulator of immunity. Biochem Soc Trans. 1997;25:466–70.
168. Hexham JM, Carayannopoulos L, Capra JD.Structure and function in IgA.Chem Immunol.
1997;65:73–87.
169. Abbas A, Lichtman A, Pillai S. B cell activation and antibody production. Cellular and
Molecular Immunology. NewYork: Elsevier, W.B. Saunders; 2012. p.243–68.
170. Kikuchi K, Lian ZX, Yang GX, Ansari AA, Ikehara S, Kaplan M, Miyakawa H, etal. Bacterial
CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis.
Gastroenterology. 2005;128:304–12.
171. Moritoki Y, Lian ZX, Wulff H, Yang GX, Chuang YH, Lan RY, Ueno Y, etal. AMA produc-
tion in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by
potassium channel blockers. Hepatology. 2007;45:314–22.
172. Harada K, Shimoda S, Sato Y, Isse K, Ikeda H, Nakanuma Y.Periductal interleukin-17 pro-
duction in association with biliary innate immunity contributes to the pathogenesis of chol-
angiopathy in primary biliary cirrhosis. Clin Exp Immunol. 2009;157:261–70.
173. Odin JA, Huebert RC, Casciola-Rosen L, LaRusso NF, Rosen A.Bcl-2-dependent oxidation
of pyruvate dehydrogenase-E2, a primary biliary cirrhosis autoantigen, during apoptosis. J
Clin Invest. 2001;108:223–32.
174. Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, Huebert RC, et al. T cell tar-
geting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J
Autoimmun. 2006;27:232–41.
175. Allina J, Stanca CM, Garber J, Hu B, Sautes-Fridman C, Bach N, Odin JA.Anti-CD16
autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. J
Autoimmun. 2008;30:238–45.
176. Rong G, Zhong R, Lleo A, Leung PS, Bowlus CL, Yang GX, Yang CY, etal. Epithelial cell
specicity and apotope recognition by serum autoantibodies in primary biliary cirrhosis.
Hepatology. 2011;54:196–203.
177. Lleo A, Selmi C, Invernizzi P, Podda M, Coppel RL, Mackay IR, Gores GJ, etal. Apotopes
and the biliary specicity of primary biliary cirrhosis. Hepatology. 2009;49:871–9.
178. Lleo A, Bowlus CL, Yang GX, Invernizzi P, Podda M, Van de Water J, Ansari AA, et al.
Biliary apotopes and anti-mitochondrial antibodies activate innate immune responses in pri-
mary biliary cirrhosis. Hepatology. 2010;52:987–98.
3
Primary Biliary Cholangitis
https://t.me/medicina_free
74
179. Abbas A, Lichtman A, Pillai S.Effector mechanisms of humoral immunity. In: Cellular and
molecular immunology. NewYork: Elsevier, W.B. Saunders; 2012. p.269–92.
180. Prieto J, Qian C, Garcia N, Diez J, Medina JF.Abnormal expression of anion exchanger
genes in primary biliary cirrhosis. Gastroenterology. 1993;105:572–8.
181. Ros E, Garcia-Puges A, Reixach M, Cuso E, Rodes J.Fat digestion and exocrine pancreatic
function in primary biliary cirrhosis. Gastroenterology. 1984;87:180–7.
182. Epstein O, Chapman RW, Lake-Bakaar G, Foo AY, Rosalki SB, Sherlock S. The pan-
creas in primary biliary cirrhosis and primary sclerosing cholangitis. Gastroenterology.
1982;83:1177–82.
183. Lake-Bakaar G, McKavanagh S, Rubio CE, Epstein O, Summereld JA.Measurement of
trypsin in duodenal juice by radioimmunoassay. Gut. 1980;21:402–7.
184. Tsuneyama K, Van De Water J, Yamazaki K, Suzuki K, Sato S, Takeda Y, Ruebner B, etal.
Primary biliary cirrhosis an epithelitis: evidence of abnormal salivary gland immunohisto-
chemistry. Autoimmunity. 1997;26:23–31.
185. Muratori P, Muratori L, Ferrari R, Cassani F, Bianchi G, Lenzi M, Rodrigo L, et al.
Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.
Am J Gastroenterol. 2003;98:431–7.
186. Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, etal.
Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/membranous’
patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther.
2006;24:1575–83.
187. Szostecki C, Guldner HH, Netter HJ, Will H.Isolation and characterization of cDNA encod-
ing a human nuclear antigen predominantly recognized by autoantibodies from patients with
primary biliary cirrhosis. J Immunol. 1990;145:4338–47.
188. Sternsdorf T, Guldner HH, Szostecki C, Grotzinger T, Will H.Two nuclear dot-associated
proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary
cirrhosis. Scand J Immunol. 1995;42:257–68.
189. Lassoued K, Brenard R, Degos F, Courvalin JC, Andre C, Danon F, Brouet JC, et al.
Antinuclear antibodies directed to a 200-kilodalton polypeptide of the nuclear envelope in
primary biliary cirrhosis. A clinical and immunological study of a series of 150 patients with
primary biliary cirrhosis. Gastroenterology. 1990;99:181–6.
190. Wesierska-Gadek J, Hohenuer H, Hitchman E, Penner E.Autoantibodies against nucleoporin
p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology. 1996;110:840–7.
191. Courvalin JC, Lassoued K, Worman HJ, Blobel G.Identication and characterization of auto-
antibodies against the nuclear envelope Lamin B receptor from patients with primary biliary
cirrhosis. J Exp Med. 1990;172:961–7.
192. Parveen S, Morshed SA, Nishioka M.High prevalence of antibodies to recombinant CENP-B
in primary biliary cirrhosis: nuclear immunouorescence patterns and ELISA reactivities. J
Gastroenterol Hepatol. 1995;10:438–45.
193. Szostecki C, Will H, Netter HJ, Guldner HH.Autoantibodies to the nuclear Sp100 protein
in primary biliary cirrhosis and associated diseases: epitope specicity and immunoglobulin
class distribution. Scand J Immunol. 1992;36:555–64.
194. Zuchner D, Sternsdorf T, Szostecki C, Heathcote EJ, Cauch-Dudek K, Will H.Prevalence,
kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic
leukemia protein in a large cohort of patients with primary biliary cirrhosis. Hepatology.
1997;26:1123–30.
195. Granito A, Yang WH, Muratori L, Lim MJ, Nakajima A, Ferri S, Pappas G, etal. PML
nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J
Gastroenterol. 2010;105:125–31.
196. Lassoued K, Guilly MN, Andre C, Paintrand M, Dhumeaux D, Danon F, Brouet JC, etal.
Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of
primary biliary cirrhosis. Clin Exp Immunol. 1988;74:283–8.
N. V. Bergasa
https://t.me/medicina_free
75
197. Nickowitz RE, Worman HJ.Autoantibodies from patients with primary biliary cirrhosis rec-
ognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein
Gp210. J Exp Med. 1993;178:2237–42.
198. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, Takii Y, etal. Anti-gp210
and anti-centromere antibodies are different risk factors for the progression of primary biliary
cirrhosis. Hepatology. 2007;45:118–27.
199. Krams SM, Van de Water J, Coppel RL, Esquivel C, Roberts J, Ansari A, Gershwin
ME.Analysis of hepatic T lymphocyte and immunoglobulin deposits in patients with primary
biliary cirrhosis. Hepatology. 1990;12:306–13.
200. Bjorkland A, Festin R, Mendel-Hartvig I, Nyberg A, Loof L, Totterman TH.Blood and liver-
inltrating lymphocytes in primary biliary cirrhosis: increase in activated T and natural killer
cells and recruitment of primed memory T cells. Hepatology. 1991;13:1106–11.
201. Nakanuma Y.Distribution of B lymphocytes in nonsuppurative cholangitis in primary biliary
cirrhosis. Hepatology. 1993;18:570–5.
202. Terasaki S, Nakanuma Y, Yamazaki M, Unoura M.Eosinophilic inltration of the liver in
primary biliary cirrhosis: a morphological study. Hepatology. 1993;17:206–12.
203. Bjorkland A, Loof L, Mendel-Hartvig I, Totterman TH.Primary biliary cirrhosis. High pro-
portions of B cells in blood and liver tissue produce anti-mitochondrial antibodies of several
Ig classes. J Immunol. 1994;153:2750–7.
204. Goldstein NS, Soman A, Gordon SC.Portal tract eosinophils and hepatocyte cytokeratin 7
immunoreactivity helps distinguish early-stage, mildly active primary biliary cirrhosis and
autoimmune hepatitis. Am J Clin Pathol. 2001;116:846–53.
205. Kita H, Naidenko OV, Kronenberg M, Ansari AA, Rogers P, He XS, Koning F, et al.
Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis
using a human CD1d tetramer. Gastroenterology. 2002;123:1031–43.
206. Daniels JA, Torbenson M, Anders RA, Boitnott JK.Immunostaining of plasma cells in pri-
mary biliary cirrhosis. Am J Clin Pathol. 2009;131:243–9.
207. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive
cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol.
1978;379:103–12.
208. Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel
RL. Primary biliary cirrhosis: an orchestrated immune response against epithelial cells.
Immunol Rev. 2000;174:210–25.
209. Kaplan MM, Gershwin ME.Primary biliary cirrhosis. N Engl J Med. 2005;353:1261–73.
210. Kita H, Matsumura S, He XS, Ansari AA, Lian ZX, Van de Water J, Coppel RL, et al.
Quantitative and functional analysis of PDC-E2-specic autoreactive cytotoxic T lympho-
cytes in primary biliary cirrhosis. J Clin Invest. 2002;109:1231–40.
211. Hashimoto E, Lindor KD, Homburger HA, Dickson ER, Czaja AJ, Wiesner RH, Ludwig
J.Immunohistochemical characterization of hepatic lymphocytes in primary biliary cirrhosis
in comparison with primary sclerosing cholangitis and autoimmune chronic active hepatitis.
Mayo Clin Proc. 1993;68:1049–55.
212. Harada K.In situ nucleic acid hybridization of cytokines in primary biliary cirrhosis: pre-
dominance of the Th1 subset. Hepatology. 1997;25:791–6.
213. Lohr HF, Schlaak JF, Gerken G, Fleischer B, Dienes HP, Meyer zum Buschenfelde
KH.Phenotypical analysis and cytokine release of liver-inltrating and peripheral blood T
lymphocytes from patients with chronic hepatitis of different etiology. Liver. 1994;14:161–6.
214. Diu A, Moebius U, Ferradini L, Genevee C, Roman-Roman S, Claudon M, Delorme D, etal.
Limited T-cell receptor diversity in liver-inltrating lymphocytes from patients with primary
biliary cirrhosis. J Autoimmun. 1993;6:611–9.
215. Martins EB, Graham AK, Chapman RW, Fleming KA.Elevation of gamma delta T lympho-
cytes in peripheral blood and livers of patients with primary sclerosing cholangitis and other
autoimmune liver diseases. Hepatology. 1996;23:988–93.
3
Primary Biliary Cholangitis
https://t.me/medicina_free
76
216. Abbas A, Lichtman A, Pillai S. Immunologic tolerance and autoimmunity. In: Abbas A,
Lichtman A, Pillai S, editors. Cellular and molecular immunology. New York: Elsevier,
W.B. Saunders; 2012. p.319–43.
217. Lan RY, Cheng C, Lian ZX, Tsuneyama K, Yang GX, Moritoki Y, Chuang YH, etal. Liver-
targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis.
Hepatology. 2006;43:729–37.
218. Wang D, Zhang H, Liang J, Gu Z, Zhou Q, Fan X, Hou Y, et al. CD4+ CD25+ but not
CD4+ Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis. Cell Mol Immunol.
2010;7:485–90.
219. Bernuzzi F, Fenoglio D, Battaglia F, Fravega M, Gershwin ME, Indiveri F, Ansari AA, etal.
Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis.
J Autoimmun. 2010;35:176–80.
220. Takahashi T, Miura T, Nakamura J, Yamada S, Miura T, Yanagi M, Matsuda Y, etal. Plasma
cells and the chronic nonsuppurative destructive cholangitis of primary biliary cirrhosis.
Hepatology. 2012;55:846–55.
221. Li SX, Lv TT, Zhang CP, Wang TQ, Tian D, Sun GY, Wang Y, et al. Alteration of liver-
inltrated and peripheral blood double-negative T-cells in primary biliary cholangitis. Liver
Int. 2019;39:1755–67.
222. You Z, Wang Q, Bian Z, Liu Y, Han X, Peng Y, Shen L, etal. The immunopathology of liver
granulomas in primary biliary cirrhosis. J Autoimmun. 2012;39:216–21.
223. Harada K, Shimoda S, Ikeda H, Chiba M, Hsu M, Sato Y, Kobayashi M, etal. Signicance
of periductal Langerhans cells and biliary epithelial cell-derived macrophage inammatory
protein-3alpha in the pathogenesis of primary biliary cirrhosis. Liver Int. 2010;31:245–53.
224. Abbas A, Lichtman A, Pillai S.Innate immunity. In: Abbas A, Lichtman A, Pillai S, editors.
Cellular and molecular immunology. NewYork: Elsevier, W.B. Saunders; 2012. p.55–88.
225. Leon MP, Bassendine MF, Gibbs P, Thick M, Kirby JA.Immunogenicity of biliary epithelium:
study of the adhesive interaction with lymphocytes. Gastroenterology. 1997;112:968–77.
226. Lechler R, Chai JG, Marelli-Berg F, Lombardi G. The contributions of T-cell anergy to
peripheral T-cell tolerance. Immunology. 2001;103:262–9.
227. Shimoda S, Harada K, Niiro H, Yoshizumi T, Soejima Y, Taketomi A, Maehara Y, etal. Biliary
epithelial cells and primary biliary cirrhosis: the role of liver-inltrating mononuclear cells.
Hepatology. 2008;47:958–65.
228. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, etal. A new class
of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640–4.
229. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, et al.
Identication and molecular characterization of fractalkine receptor CX3CR1, which medi-
ates both leukocyte migration and adhesion. Cell. 1997;91:521–30.
230. Isse K, Harada K, Zen Y, Kamihira T, Shimoda S, Harada M, Nakanuma Y.Fractalkine and
CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile
ducts. Hepatology. 2005;41:506–16.
231. Shimoda S, Harada K, Niiro H, Taketomi A, Maehara Y, Tsuneyama K, Kikuchi K, etal.
CX3CL1 (fractalkine): a signpost for biliary inammation in primary biliary cirrhosis.
Hepatology. 2010;51:567–75.
232. Funaro A, Malavasi F.Human CD38, a surface receptor, an enzyme, an adhesion molecule
and not a simple marker. J Biol Regul Homeost Agents. 1999;13:54–61.
233. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, etal.
Report of the European myeloma network on multiparametric ow cytometry in multiple
myeloma and related disorders. Haematologica. 2008;93:431–8.
234. Chuang YH, Lian ZX, Tsuneyama K, Chiang BL, Ansari AA, Coppel RL, Gershwin
ME.Increased killing activity and decreased cytokine production in NK cells in patients with
primary biliary cirrhosis. J Autoimmun. 2006;26:232–40.
N. V. Bergasa
https://t.me/medicina_free
77
235. Shimoda S, Harada K, Niiro H, Shirabe K, Taketomi A, Maehara Y, Tsuneyama K, etal.
Interaction between toll-like receptors and natural killer cells in the destruction of bile ducts
in primary biliary cirrhosis. Hepatology. 2011;53:1270–81.
236. Yin XM, Ding WX, Gao W.Autophagy in the liver. Hepatology. 2008;47:1773–85.
237. Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Autophagy mediates the process of cellu-
lar senescence characterizing bile duct damages in primary biliary cirrhosis. Lab Investig.
2010;90:835–43.
238. Sasaki M, Miyakoshi M, Sato Y, Nakanuma Y. Modulation of the microenvironment by
senescent biliary epithelial cells may be involved in the pathogenesis of primary biliary cir-
rhosis. J Hepatol. 2010;53:318–25.
239. Sasaki M, Yoshimura-Miyakoshi M, Sato Y, Nakanuma Y.A possible involvement of endo-
plasmic reticulum stress in biliary epithelial autophagy and senescence in primary biliary
cirrhosis. J Gastroenterol. 2015;50:984–95.
240. Sasaki M, Sato Y, Nakanuma Y.An impaired biliary bicarbonate umbrella may be involved in
dysregulated autophagy in primary biliary cholangitis. Lab Investig. 2018;98:745–54.
241. Sasaki M, Sato Y, Nakanuma Y. Increased p16(INK4a)-expressing senescent bile ductular
cells are associated with inadequate response to ursodeoxycholic acid in primary biliary chol-
angitis. J Autoimmun. 2019;107:102377.
242. Mao TK, Davis PA, Odin JA, Coppel RL, Gershwin ME.Sidechain biology and the immu-
nogenicity of PDC-E2, the major autoantigen of primary biliary cirrhosis. Hepatology.
2004;40:1241–8.
243. Tsuda M, Ambrosini YM, Zhang W, Yang GX, Ando Y, Rong G, Tsuneyama K, etal. Fine
phenotypic and functional characterization of effector cluster of differentiation 8 positive T
cells in human patients with primary biliary cirrhosis. Hepatology. 2011;54:1293–302.
244. Tomiyama H, Matsuda T, Takiguchi M.Differentiation of human CD8(+) T cells from a
memory to memory/effector phenotype. J Immunol. 2002;168:5538–50.
245. Morikawa K, Oseko F, Morikawa S, Imai K, Sawada M.Recombinant human IL-5 augments
immunoglobulin generation by human B lymphocytes in the presence of IL-2. Cell Immunol.
1993;149:390–401.
246. Krams SM, Cao S, Hayashi M, Villanueva JC, Martinez OM.Elevations in IFN-gamma,
IL-5, and IL-10in patients with the autoimmune disease primary biliary cirrhosis: association
with autoantibodies and soluble CD30. Clin Immunol Immunopathol. 1996;80:311–20.
247. MacGregor GA.Primary biliary cirrhosis is a dry-gland syndrome. Lancet. 1980;2:535.
248. Paumgartner G, Beuers U.Ursodeoxycholic acid in cholestatic liver disease: mechanisms of
action and therapeutic use revisited. Hepatology. 2002;36:525–31.
249. Neuman MG, Cameron RG, Haber JA, Katz GG, Blendis LM.An electron microscopic
and morphometric study of ursodeoxycholic effect in primary biliary cirrhosis. Liver.
2002;22:235–44.
250. Siegel J, Jorgensen R, Angulo P, Lindor K. Treatment with ursodeoxycholic acid is asso-
ciated with weight gain in patients with primary biliary cirrhosis. J Clin Gastgroenterol.
2003;37:185.
251. LiverTox: clinical and research information on drug-induced liver injury [Internet].
Review; 2012.
252. Poupon RE, Lindor KD, Pares A, Chazouilleres O, Poupon R, Heathcote EJ.Combined anal-
ysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary
biliary cirrhosis. J Hepatol. 2003;39:12–6.
253. Combes B, Markin RS, Wheeler DE, Rubin R, West AB, Mills AS, Eigenbrodt EH, etal.
The effect of ursodeoxycholic acid on the orid duct lesion of primary biliary cirrhosis.
Hepatology. 1999;30:602–5.
254. Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, Ishii H.A novel treatment
for refractory primary biliary cirrhosis? Hepato-Gastroenterology. 2000;47:1518–21.
255. Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K.Fenobrate for
patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol. 2004;10:894–8.
3
Primary Biliary Cholangitis
https://t.me/medicina_free
78
256. Bergasa NV, Jones A, Kleiner DE, Rabin L, Park Y, Wells MC, Hoofnagle JH. Pilot study
of low dose oral methotrexate treatment for primary biliary cirrhosis. Am J Gastroenterol.
1996;91:295–9.
257. Lindor KD, Dickson ER, Jorgensen RA, Anderson ML, Wiesner RH, Gores GJ, Lange SM,
etal. The combination of ursodeoxycholic acid and methotrexate for patients with primary
biliary cirrhosis: the results of a pilot study. Hepatology. 1995;22:1158–62.
258. Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, etal.
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary
cirrhosis. Hepatology. 2005;42:1184–93.
259. Leung J, Bonis PA, Kaplan MM.Colchicine or methotrexate, with ursodiol, are effective after
20 years in a subset of patients with primary biliary cirrhosis. Clin Gastroenterol Hepatol.
2011;9:776–80.
260. Heathcote J, Ross A, Sherlock S.A prospective controlled trial of azathioprine in primary
biliary cirrhosis. Gastroenterology. 1976;70:656–60.
261. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, Doniach D, etal.
Benecial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis.
Final results of an international trial. Gastroenterology. 1985;89:1084–91.
262. Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane
Database Syst Rev. 2007;18:CD006000.
263. Neuberger J, Christensen E, Portmann B, Caballeria J, Rodes J, Ranek L, Tygstrup N, etal.
Double blind controlled trial of d-penicillamine in patients with primary biliary cirrhosis.
Gut. 1985;26:114–9.
264. Gong Y, Frederiksen SL, Gluud C.D-penicillamine for primary biliary cirrhosis. Cochrane
Database Syst Rev. 2004;18:CD004789.
265. Gong Y, Klingenberg SL, Gluud C.Systematic review and meta-analysis: D-Penicillamine
vs. placebo/no intervention in patients with primary biliary cirrhosis– Cochrane Hepato-
biliary group. Aliment Pharmacol Ther. 2006;24:1535–44.
266. Kaplan MM, Alling DW, Zimmerman HJ, Wolfe HJ, Sepersky RA, Hirsch GS, Elta
GH, et al. A prospective trial of colchicine for primary biliary cirrhosis. N Engl J Med.
1986;315:1448–54.
267. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database Syst Rev.
2004;2:CD004481.
268. Gong Y, Gluud C.Colchicine for primary biliary cirrhosis: a Cochrane Hepato-biliary group
systematic review of randomized clinical trials. Am J Gastroenterol. 2005;100:1876–85.
269. Minuk GY, Bohme CE, Burgess E, Hersheld NB, Kelly JK, Shaffer EA, Sutherland LR,
et al. Pilot study of cyclosporin a in patients with symptomatic primary biliary cirrhosis.
Gastroenterology. 1988;95:1356–63.
270. Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, Dickson
ER.A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis [see com-
ments]. N Engl J Med. 1990;322:1419–24.
271. Gong Y, Christensen E, Gluud C. Cyclosporin a for primary biliary cirrhosis. Cochrane
Database Syst Rev. 2007;3:CD005526.
272. Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, Hanson RG,
et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology.
1986;91:1327–34.
273. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF.A controlled
trial of prednisolone treatment in primary biliary cirrhosis. Three-year results. J Hepatol.
1992;15:336–44.
274. Mitchison HC, Bassendine MF, Malcolm AJ, Watson AJ, Record CO, James OF. A pilot,
double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis:
hepatic improvement but greater bone loss. Hepatology. 1989;10:420–9.
275. Kaplan MM, Knox TA.Treatment of primary biliary cirrhosis with low-dose weekly metho-
trexate [see comments]. Gastroenterology. 1991;101:1332–8.
N. V. Bergasa
https://t.me/medicina_free
79
276. Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Dickson ER.Effects of ursode-
oxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology.
1996;110:1515–8.
277. Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxy-
cholic acid therapy on liver brosis progression in primary biliary cirrhosis. Hepatology.
2000;32:1196–9.
278. Lindor KD, Jorgensen RA, Therneau TM, Malinchoc M, Dickson ER. Ursodeoxycholic
acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc.
1997;72:1137–40.
279. Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R.The effect of ursode-
oxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology.
2005;128:297–303.
280. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary
biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology.
2006;130:715–20.
281. Huet PM, Vincent C, Deslaurier J, Cote J, Matsutami S, Boileau R, Huet-van KJ. Portal
hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treat-
ment. Gastroenterology. 2008;135:1552–60.
282. Combes B, Luketic VA, Peters MG, Zetterman RK, Garcia-Tsao G, Munoz SJ, Lin D, etal.
Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for
primary biliary cirrhosis. Am J Gastroenterol. 2004;99:264–8.
283. Gong Y, Huang ZB, Christensen E, Gluud C.Ursodeoxycholic acid for primary biliary cir-
rhosis. Cochrane Database Syst Rev. 2008;3:CD000551.
284. Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, Ackermann H,
etal. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis:
results of a prospective double-blind trial. Gastroenterology. 1999;117:918–25.
285. Rautiainen H, Karkkainen P, Karvonen AL, Nurmi H, Pikkarainen P, Nuutinen H, Farkkila
M.Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis:
a three-year randomized trial. Hepatology. 2005;41:747–52.
286. Wolfhagen FH, van Hoogstraten HJ, van Buuren HR, van Berge-Henegouwen GP, ten Kate
FJ, Hop WC, van der Hoek EW, etal. Triple therapy with ursodeoxycholic acid, prednisone
and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study.
J Hepatol. 1998;29:736–42.
287. Almasio PL, Floreani A, Chiaramonte M, Provenzano G, Battezzati P, Crosignani A, Podda
M, et al. Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with
or without colchicine in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther.
2000;14:1645–52.
288. Gong Y, Gluud C.Methotrexate for primary biliary cirrhosis. Cochrane Database Syst Rev.
2005;3:CD004385.
289. https://www.accessdata.fda.gov Ocaliva- Accessdata.fda.gov
290. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, etal. A
placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med.
2016;375:631–43.
291. Hirscheld GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, etal.
Efcacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response
to ursodeoxycholic acid. Gastroenterology. 2015;148:751–61.
292. Kowdley KV, Luketic V, Chapman R, Hirscheld GM, Poupon R, Schramm C, Vincent C,
etal. A randomized trial of obeticholic acid monotherapy in patients with primary biliary
cholangitis. Hepatology. 2018;67:1890–902.
293. Bowlus CL, Pockros PJ, Kremer AE, Pares A, Forman LM, JPH D, Ryder SD, etal. Long-
term obeticholic acid therapy improves histological endpoints in patients with primary biliary
cholangitis. Clin Gastroenterol Hepatol. 2019;18(5):1170–1178.e6.
3
Primary Biliary Cholangitis
https://t.me/medicina_free
80
294. Summereld JA, Elias E, Sherlock S.Effects of clobrate in primary biliary cirrhosis hyper-
cholesterolemia and gallstones. Gastroenterology. 1975;69:998–1000.
295. Sherlock S. Cholestasis. In: Diseases of the liver and biliary system. Oxford: Blackwell
Scientic Publications; 1981. p.209–43.
296. WHO cooperative trial on primary prevention of ischaemic heart disease with clobrate to
lower serum cholesterol: nal mortality follow-up. Report of the Committee of Principal
Investigators. Lancet. 1984;2:600–4.
297. Oliver M. The clobrate saga: a retrospective commentary. Br J Clin Pharmacol.
2012;74:907–10.
298. Fruchart JC, Duriez P.Mode of action of brates in the regulation of triglyceride and HDL-
cholesterol metabolism. Drugs Today (Barc). 2006;42:39–64.
299. Tenenbaum A, Motro M, Fisman EZ.Dual and pan-peroxisome proliferator-activated recep-
tors (PPAR) co-agonism: the bezabrate lessons. Cardiovasc Diabetol. 2005;4:14.
300. Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, Maeda T, Onishi S.Bezabrate may
have a benecial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res. 1999;16:12–8.
301. Kanda T, Yokosuka O, Imazeki F, Saisho H.Bezabrate treatment: a new medical approach
for PBC patients? J Gastroenterol. 2003;38:573–8.
302. Nakamuta M, Fujino T, Yada R, Yasutake K, Yoshimoto T, Harada N, Yada M, et al.
Therapeutic effect of bezabrate against biliary damage: a study of phospholipid secretion
via the PPARalpha-MDR3 pathway. Int J Clin Pharmacol Ther. 2010;48:22–8.
303. Hazzan R, Tur-Kaspa R.Bezabrate treatment of primary biliary cirrhosis following incom-
plete response to ursodeoxycholic acid. J Clin Gastroenterol. 2010;44:371–3.
304. Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, Saito Y, et al.
Anticholestatic effects of bezabrate in patients with primary biliary cirrhosis treated with
ursodeoxycholic acid. Hepatology. 2013;57:1931–41.
305. Hosonuma K, Sato K, Yamazaki Y, Yanagisawa M, Hashizume H, Horiguchi N, Kakizaki
S, etal. A prospective randomized controlled study of long-term combination therapy using
ursodeoxycholic acid and bezabrate in patients with primary biliary cirrhosis and dyslipid-
emia. Am J Gastroenterol. 2015;110:423–31.
306. Corpechot C, Chazouilleres O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria
O, etal. A placebo-controlled trial of bezabrate in primary biliary cholangitis. N Engl J
Med. 2018;378:2171–81.
307. Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, etal.
Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary bili-
ary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, ran-
domised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterol Hepatol.
2017;2:716–26.
308. Bowlus CA, Hirscheld G, Bacon B, Galambos M, Harrison S, Odin J, Amato G, Steinberg
S, Rosenbusch S, Bergheanu S, Boudes P.Safety and efcacy of seladelpar in patients with
primary biliary cholangitis with cirrhosis. Hepatology. 2019;70:1898.
309. Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, et al. A ran-
domized placebo-controlled trial of elabranor in patients with primary biliary cholangitis
and incomplete response to UDCA.J Hepatol. 2021;74(6):1344–54.
310. Lammers WJ, van Buuren HR, Hirscheld GM, Janssen HL, Invernizzi P, Mason AL,
Ponsioen CY, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points
of outcomes of patients with primary biliary cirrhosis: an international follow-up study.
Gastroenterology. 2014;147:1338–1349 e1335.
311. Lammers WJ, Hirscheld GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, Floreani
A, et al. Development and validation of a scoring system to predict outcomes of patients
with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology.
2015;149:1804–12.
N. V. Bergasa
https://t.me/medicina_free
81
312. Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Grifths L, etal. The
UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction
of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016;63:930–50.
313. Efe C, Tascilar K, Henriksson I, Lytvyak E, Alalkim F, Trivedi H, Eren F, etal. Validation of
risk scoring systems in ursodeoxycholic acid-treated patients with primary biliary cholangi-
tis. Am J Gastroenterol. 2019;114:1101–8.
314. Gluud C, Brok J, Gong Y, Koretz RL.Hepatology may have problems with putative surrogate
outcome measures. J Hepatol. 2007;46:734–42.
315. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ.Fatigue in primary biliary cirrhosis.
Gut. 1998;43:705–10.
316. Goldblatt J, James OF, Jones DE.Grip strength and subjective fatigue in patients with pri-
mary biliary cirrhosis. JAMA. 2001;285:2196–7.
317. Lemp MA.Report of the National Eye Institute/industry workshop on clinical trials in dry
eyes. CLAO J. 1995;21:221–32.
318. Aragona P, Papa V, Micali A, Santocono M, Milazzo G.Long term treatment with sodium
hyaluronate-containing articial tears reduces ocular surface damage in patients with dry eye.
Br J Ophthalmol. 2002;86:181–4.
319. Tatlipinar S, Akpek EK.Topical ciclosporin in the treatment of ocular surface disorders. Br J
Ophthalmol. 2005;89:1363–7.
320. Hamano T. Lacrimal duct occlusion for the treatment of dry eye. Semin Ophthalmol.
2005;20:71–4.
321. Alves M, Novaes P, Morraye Mde A, Reinach PS, Rocha EM.Is dry eye an environmental
disease? Arq Bras Oftalmol. 2014;77:193–200.
322. Wolkoff P.The mystery of dry indoor air- an overview. Environ Int. 2018;121:1058–65.
323. Richards A, Rooney J, Prime S, Scully C.Primary biliary cirrhosis. Sole presentation with
rampant dental caries. Oral Surg Oral Med Oral Pathol. 1994;77:16–8.
324. Olsson H, Spak CJ, Axell T.The effect of a chewing gum on salivary secretion, oral muco-
sal friction, and the feeling of dry mouth in xerostomic patients. Acta Odontol Scand.
1991;49:273–9.
325. Alsakran AM. Update knowledge of dry mouth - a guideline for dentists. Afr Health Sci.
2014;14:736–42.
326. Izumi M, Eguchi K, Nakamura H, Takagi Y, Kawabe Y, Nakamura T.Corticosteroid irrigation
of parotid gland for treatment of xerostomia in patients with Sjogren’s syndrome. Ann Rheum
Dis. 1998;57:464–9.
327. Mavragani CP, Moutsopoulos HM. Conventional therapy of Sjogren’s syndrome. Clin Rev
Allergy Immunol. 2007;32:284–91.
328. Mavragani CP.Mechanisms and new strategies for primary Sjogren’s syndrome. Annu Rev
Med. 2017;68:331–43.
329. Mang FW, Michieletti P, O’Rourke K, Cauch-Dudek K, Diamant N, Bookman A, Heathcote
J.Primary biliary cirrhosis, sicca complex, and dysphagia. Dysphagia. 1997;12:167–70.
330. Romao VC, Talarico R, Scire CA, Vieira A, Alexander T, Baldini C, Gottenberg JE,
et al. Sjogren’s syndrome: state of the art on clinical practice guidelines. RMD Open.
2018;4:e000789.
331. Floreani A, Mega A, Camozzi V, Baldo V, Plebani M, Burra P, Luisetto G.Is osteoporosis a
peculiar association with primary biliary cirrhosis? World J Gastroenterol. 2005;11:5347–50.
332. Boulton-Jones JR, Fenn RM, West J, Logan RF, Ryder SD. Fracture risk of women with
primary biliary cirrhosis: no increase compared with general population controls. Aliment
Pharmacol Ther. 2004;20:551–7.
333. Guanabens N, Pares A, del Rio L, Roca M, Gomez R, Munoz J, Rodes J.Sodium uoride
prevents bone loss in primary biliary cirrhosis. J Hepatol. 1992;15:345–9.
334. Camisasca M, Crosignani A, Battezzati PM, Albisetti W, Grandinetti G, Pietrogrande L, Bif
A, etal. Parenteral calcitonin for metabolic bone disease associated with primary biliary cir-
rhosis. Hepatology. 1994;20:633–7.
3
Primary Biliary Cholangitis
https://t.me/medicina_free
Соседние файлы в папке Библиотека им академика М.И. Перельмана